Finasteride Does NOT Cause Urinary Retention
Finasteride significantly reduces the risk of acute urinary retention (AUR) in men with benign prostatic hyperplasia, rather than causing it. This is one of the primary therapeutic benefits of the medication, supported by high-quality evidence from FDA labeling and major clinical trials 1.
Evidence for Risk Reduction
The FDA-approved indication for finasteride explicitly states it is used to "reduce the risk of acute urinary retention" in men with symptomatic BPH 1. This approval is based on robust clinical trial data:
The landmark PLESS trial (3,040 men followed for 4 years) demonstrated that finasteride reduced the risk of AUR by 57% compared to placebo (2.8% vs 6.6%; 95% CI: 40-69% risk reduction) 2. This benefit was sustained through 6 years of follow-up 3.
The MTOPS trial showed finasteride reduced AUR risk by 67% compared to placebo (0.8% vs 2.4%) 4.
The 2023 European Association of Urology guidelines cite these same studies, confirming that finasteride "significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia" 5.
Mechanism of Benefit
Finasteride works by inhibiting 5-alpha reductase, which blocks conversion of testosterone to dihydrotestosterone (DHT). This leads to:
- Prostate volume reduction of approximately 18% over 4 years 1
- Improved urinary flow rates (mean increase of 1.9 mL/sec vs 0.2 mL/sec with placebo) 1
- Symptom score improvement (mean decrease of 3.3 points vs 1.3 points with placebo on a 0-34 scale) 1
These physiological changes directly reduce bladder outlet obstruction, thereby preventing rather than causing urinary retention.
Clinical Context
The 2021 AUA guidelines recommend finasteride for men with prostates >30cc who have moderate-to-severe LUTS, specifically to prevent disease progression including AUR 6. The medication takes 6-12 months to achieve maximal benefit, as prostate shrinkage occurs gradually 1.
Important Caveat
Early in treatment (first few weeks), some men with severe baseline obstruction might theoretically experience worsening symptoms before improvement occurs, but this is not a documented adverse effect in the clinical trials. If a patient develops AUR while on finasteride, this represents disease progression despite treatment, not a drug-induced event. In such cases, alpha-blockers should be added or surgical intervention considered 6.
Actual Adverse Effects
The documented adverse effects of finasteride are sexual in nature (decreased libido, erectile dysfunction, ejaculation disorders), not urinary retention 1, 7. Compared to alpha-blockers like doxazosin, finasteride has significantly lower rates of dizziness, postural hypotension, and asthenia 7.